Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:18:08.395Z.
Calculation as of: 2026-10-06T21:18:08.395Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f5be79ac0e7715def3f298c248b41853c7a510be646acbaec4ce361b11b20d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$23.38M
EBITDA Yield
N/A
TTM Avg
217.80%
3Y Avg
229.94%
5Y Avg
229.94%
Market Cap
$22.00M
EBITDA Yield
N/A
TTM Avg
24.06%
3Y Avg
27.42%
5Y Avg
27.42%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rein Therapeutics Inc. (RNTX) | $23.06M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.38M | N/A | 217.80% | 229.94% | 229.94% |
| LeonaBio, Inc. (LONA)vs › | $22.68M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | 24.06% | 27.42% | 27.42% |
| Kyntra Bio, Inc. (KYNB)vs › | $24.13M | N/A | 1.43% | 1.43% | 1.43% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $24.60M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | N/A | 0.01% | 0.01% | 0.01% |
| NextCure, Inc. (NXTC)vs › | $20.53M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
